LBA30 Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study

T. Mazard; F. Ghiringhelli; A. Winter; C. de la Fouchardiere; D. Botsen; T. André; J. Vanbockstael; M. Dos Santos; J. Martin-Babau; Y. Rinaldi; L. Evesque; S. Ellis; C. Gavoille; D. Smith; M. Fonck; D. Sefrioui; V. Pezzella; S. Nougaret; A.R. Thierry; O. Bouche

doi:10.1016/j.annonc.2023.10.022

Retour

LBA30 Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study

Article de revue

Avec comité de lecture

LBA30 Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study

T. Mazard, F. Ghiringhelli, A. Winter, C. de la Fouchardiere, D. Botsen, T. André, J. Vanbockstael, M. Dos Santos, J. Martin-Babau, Y. Rinaldi, …

Annals of oncology, Vol.34, pp.S1270-S1270

10/2023

DOI: https://doi.org/10.1016/j.annonc.2023.10.022

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: LBA30 Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study
Créateurs - sans rôle: T. Mazard - Medical Oncology, ICM - Institut du Cancer de Montpellier, Montpellier, France
F. Ghiringhelli - Medical Oncology, Centre Georges-François Leclerc (Dijon), Dijon, France
A. Winter - BIOSTATISTIC, ICM - Institut du Cancer de Montpellier, Montpellier, France
C. de la Fouchardiere - Institut Paoli-Calmettes
D. Botsen - Medical Oncology Dept, Institut Jean Godinot, Reims, France
T. André - Hôpital Saint-Antoine
J. Vanbockstael - Oncology, ICO - Institut de Cancerologie de l'Ouest - Site Paul Papin, Angers, France
M. Dos Santos - Oncology, Centre Francois Baclesse, Caen, France
J. Martin-Babau - Medical Oncology Department, Hôpital Privé des Côtes d'Armor, Plérin, France
Y. Rinaldi - Digestive Oncology, Marseille European Hospital, Marseille, France
L. Evesque - Medical Oncology, Centre Anticancer Antoine Lacassagne, Nice, France
S. Ellis - Radiotherapy, Centre Catalan d'Oncologie Clinique St. Pierre, Perpignan, France
C. Gavoille - Institut de Cancérologie de Lorraine
D. Smith - Oncology, Hopital Haut Leveque, Pessac, France
M. Fonck - Oncology, Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, France
D. Sefrioui - Oncology, Hopital Charles-Nicolle - CHU de Rouen, Rouen, France
V. Pezzella - Digestive Department, Unicancer, Paris, France
S. Nougaret - Radiology, ICM - Institut du Cancer de Montpellier, Montpellier, France
A.R. Thierry - Institut de Recherche en Cancérologie de Montpellier
O. Bouche - Hôpital Robert-Debré
Détails de publication: Annals of oncology, Vol.34, pp.S1270-S1270
Éditeur: Elsevier Ltd
Identifiants: 99141154909311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article